奇正藏药
(002287)
| 流通市值：125.61亿 | | | 总市值：125.87亿 |
| 流通股本：5.71亿 | | | 总股本：5.72亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 405,252,640.82 | 2,416,012,277.2 | 1,522,943,818.43 | 1,175,055,354.14 |
| 营业收入 | 405,252,640.82 | 2,416,012,277.2 | 1,522,943,818.43 | 1,175,055,354.14 |
| 二、营业总成本 | 315,927,892.39 | 1,850,672,675.76 | 1,201,047,151.05 | 845,134,478.82 |
| 营业成本 | 65,116,646.6 | 409,473,077.75 | 270,260,840.07 | 209,238,804.18 |
| 税金及附加 | 4,631,350.99 | 39,801,012.36 | 29,002,593.2 | 23,009,851.17 |
| 销售费用 | 192,569,766.54 | 1,095,623,208.03 | 685,476,145.53 | 465,680,983.38 |
| 管理费用 | 38,837,615.19 | 189,362,927.5 | 132,148,634.95 | 87,799,300.32 |
| 研发费用 | 14,953,617.7 | 81,025,618.52 | 49,651,178.73 | 32,134,569.83 |
| 财务费用 | -181,104.63 | 35,386,831.6 | 34,507,758.57 | 27,270,969.94 |
| 其中:利息费用 | 2,050,937.7 | 41,855,491.8 | 39,309,282.82 | 29,418,055.95 |
| 其中:利息收入 | 1,769,956.99 | 6,775,395.44 | 4,974,262.96 | 3,190,765.97 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 16,055,473.2 | 66,367,366.17 | 64,649,962.87 | 43,330,873.55 |
| 加:投资收益 | -1,734,369.95 | 1,723,757.9 | -5,961,941.8 | -3,930,453.82 |
| 资产处置收益 | 107,293.68 | 7,379,563.32 | 3,122,147.44 | 909,309.6 |
| 资产减值损失(新) | 147,601.88 | -982,475.87 | 586,628.3 | 766,877.8 |
| 信用减值损失(新) | 116,972.81 | -115,266.34 | -665,233.22 | -18,839.94 |
| 其他收益 | 5,062,305.12 | 128,912,243.88 | 108,237,885.1 | 48,389,216.18 |
| 四、营业利润 | 109,080,025.17 | 768,624,790.5 | 491,866,116.07 | 419,367,858.69 |
| 加:营业外收入 | 625.33 | 986,414.37 | 56,774.26 | 42,292.49 |
| 减:营业外支出 | 43,922.3 | 29,768,722.96 | 19,677,615.13 | 16,836,062.03 |
| 五、利润总额 | 109,036,728.2 | 739,842,481.91 | 472,245,275.2 | 402,574,089.15 |
| 减:所得税费用 | 15,071,795.68 | 92,368,362.68 | 48,682,030.12 | 43,121,514.86 |
| 六、净利润 | 93,964,932.52 | 647,474,119.23 | 423,563,245.08 | 359,452,574.29 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 93,964,932.52 | 647,474,119.23 | 423,563,245.08 | 359,452,574.29 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 95,179,057.87 | 648,425,430.79 | 423,519,032.46 | 358,394,175.54 |
| 少数股东损益 | -1,214,125.35 | -951,311.56 | 44,212.62 | 1,058,398.75 |
| 扣除非经常损益后的净利润 | 75,589,951.05 | 480,163,167.33 | 281,928,133.23 | 289,472,475.66 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 1.19 | 0.79 | 0.68 |
| (二)稀释每股收益 | 0.17 | 1.19 | 0.79 | 0.68 |
| 八、其他综合收益 | -1,868,313.53 | -2,798,072 | -1,805,165.44 | -160,905.25 |
| 归属于母公司股东的其他综合收益 | -1,868,313.53 | -2,798,072 | -1,805,165.44 | -160,905.25 |
| 九、综合收益总额 | 92,096,618.99 | 644,676,047.23 | 421,758,079.64 | 359,291,669.04 |
| 归属于母公司股东的综合收益总额 | 93,310,744.34 | 645,627,358.79 | 421,713,867.02 | 358,233,270.29 |
| 归属于少数股东的综合收益总额 | -1,214,125.35 | -951,311.56 | 44,212.62 | 1,058,398.75 |
| 公告日期 | 2026-04-24 | 2026-04-24 | 2025-10-28 | 2025-08-23 |
| 审计意见(境内) | | 标准无保留意见 | | |